Imunon highlights 14.7-month overall survival gain in Phase 2 IMNN-001 ovarian cancer study as Phase 3 trial advances
Bitget2026/09/24 12:05- Imunon highlighted final Phase 2 results already presented, pointing to a survival benefit for IMNN-001 in newly diagnosed advanced ovarian cancer.
- The update framed the Phase 2 findings as supportive evidence for its ongoing Phase 3 OVATION 3 trial, where survival is the primary endpoint.
- Management described the treatment as avoiding the systemic safety issues that derailed earlier IL-12 programs, supporting continued late-stage development.
- Enrollment in OVATION 3 is running ahead of plan, keeping the company’s targeted enrollment completion in the first quarter of 2029 intact.
- Imunon also cited early MRD study observations already shared, suggesting improved disease clearance signals, while noting the dataset remains too small for efficacy conclusions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AERO price prediction – Identifying the next short-term target for the altcoin
Swiss Franc remains near 16-month lows as rate hike odds lift US Dollar
Rapid rise in real interest rates, Goldman Sachs warns that 'systematic selling pressure' in US stocks is building at quarter-end
Goldman Sachs believes that the rapid rise in real interest rates has exerted more direct pressure on the US stock market, with rate-sensitive sectors such as small-cap and financial stocks being particularly affected. On the liquidity front, Goldman Sachs estimates that pension funds may sell around $3.3 billions in equities at the end of the month and quarter, and that CTAs may sell about $530 million worth of Russell 2000 index futures in the coming week. For the market, unless the issues of oil and interest rates are resolved, the AI narrative is "almost irrelevant."
USD/JPY falls below 157! The yen becomes the strongest G-10 currency, with the market betting on another rate hike by the central bank next month.
On Wednesday, the yen strengthened against the US dollar, with the USD/JPY rate falling below the 157 mark, as repeated warnings from the Japanese government regarding exchange rates and end-of-quarter capital flows provided support for the yen.
Crypto prices
More
